CA2585606A1 - High-dosage extended-release formulation of gepirone - Google Patents

High-dosage extended-release formulation of gepirone Download PDF

Info

Publication number
CA2585606A1
CA2585606A1 CA002585606A CA2585606A CA2585606A1 CA 2585606 A1 CA2585606 A1 CA 2585606A1 CA 002585606 A CA002585606 A CA 002585606A CA 2585606 A CA2585606 A CA 2585606A CA 2585606 A1 CA2585606 A1 CA 2585606A1
Authority
CA
Canada
Prior art keywords
composition
gepirone
tablet
inches
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002585606A
Other languages
English (en)
French (fr)
Inventor
Stephen J. Kramer
Louis F. Fabre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FABRE-KRAMER HOLDINGS Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2585606A1 publication Critical patent/CA2585606A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002585606A 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone Abandoned CA2585606A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/032785 WO2006052227A1 (en) 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone

Publications (1)

Publication Number Publication Date
CA2585606A1 true CA2585606A1 (en) 2006-05-18

Family

ID=36336794

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002585606A Abandoned CA2585606A1 (en) 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone

Country Status (11)

Country Link
EP (1) EP1809255A4 (ru)
JP (1) JP2008519071A (ru)
CN (1) CN101076320A (ru)
AU (1) AU2004324868B2 (ru)
BR (1) BRPI0419179A (ru)
CA (1) CA2585606A1 (ru)
EA (1) EA013213B1 (ru)
IL (1) IL182792A0 (ru)
MX (1) MX2007005368A (ru)
NO (1) NO20072851L (ru)
WO (1) WO2006052227A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131906A1 (it) 2013-11-18 2015-05-19 Gnosis Spa Composizioni solide orali a lento rilascio
RU2713725C1 (ru) * 2019-02-08 2020-02-06 Юрий Владимирович Соколов Биологически активная добавка и способ ее применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
KR20040018314A (ko) * 2000-12-08 2004-03-03 악조 노벨 엔.브이. 게피론을 함유하는 경구 투여용 연장 방출형 제제
US20030220346A1 (en) * 2000-12-18 2003-11-27 Kramer Stephen J. Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Also Published As

Publication number Publication date
NO20072851L (no) 2007-07-31
MX2007005368A (es) 2007-09-11
AU2004324868B2 (en) 2010-04-29
IL182792A0 (en) 2007-08-19
EA200701010A1 (ru) 2007-10-26
WO2006052227A1 (en) 2006-05-18
CN101076320A (zh) 2007-11-21
BRPI0419179A (pt) 2007-12-18
JP2008519071A (ja) 2008-06-05
AU2004324868A1 (en) 2006-05-18
EA013213B1 (ru) 2010-04-30
EP1809255A1 (en) 2007-07-25
EP1809255A4 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
US7226614B2 (en) Tablet comprising cetirizine and pseudoephedrine
AU702282B2 (en) Gepirone dosage form
EP1404304B1 (en) Tablet comprising cetirizine and pseudoephedrine
AU2002345024A1 (en) Tablet comprising cetirizine and pseudoephedrine
WO2009027786A2 (en) Matrix dosage forms of varenicline
US20020094345A1 (en) Pharmaceutical compositions containing epinastine and pseudoephedrine
AU2004324868B2 (en) High-dosage extended-release formulation of gepirone
US20060099267A1 (en) High-dosage extended-release formulation of gepirone
AU2002212290B2 (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
US20050171119A1 (en) Pharmaceutical formulations with modified release
WO2005065662A1 (en) Solid dosage formulations of galantamine
NZ554916A (en) High-dosage extended-release formulation of gepirone
EP1569651B1 (en) Tablet comprising efletirizine and pseudoephedrine
KR20070093972A (ko) 게피론의 고용량 서방성 제제
EP4205730A1 (en) Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
KR20200104256A (ko) 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
US20130150375A1 (en) GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
EP1713451A1 (en) Solid dosage formulations of galanthamine
EP2340813A1 (en) Solid dosage formulations of galantamine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20121105